Table 2

The demographic data and characteristics of comorbid MFS and MG (5 cases).

characteristicsCase 1Case 2Case 3Case 4Case 5
Author (yr)Mak W(2005)Silverstein MP(2008)Lau KK(2009)Tanaka Y(2016)Our case
PopulationHong Kong/ChinaUSAHong Kong/ChinaJapanChina
GenderMMFFM
Age4043846972
Preceding factors+-+--
Clinical characteristicsLimb weakness, areflexia, ptosis, ophthalmoplegiaAtaxia, areflexia, ophthalmoplegia, ptosisweakness, areflexia, ptosis, ophthalmoplegia, dysphagia, dysarthria, respiratory failureAcute bilateral ptosis, ophthalmoplegia, ataxic gait, and areflexiaAcute bilateral ptosis, ophthalmoplegia, diplopia
Albumino-cytologic dissociation+-+-+
Nerve conduction+-+-+
RNS-++++
Anti-AChR antibody+++++
Anti-GQ1b antibody+--++
Edrophonium chloride
Treatmentplasmapheresis, pyridostigmine-Pyridostigmine, IVIGIVIG, Steroidpyridostigmine, IVIG
Thymectomy----+
Prognosis10010

  • M- Male, F - Female, MG - Myasthenia gravis, MFS - Miller Fisher Syndrome, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation, Functional outcome was ranked according to the adopted scale by Hughes: 0, healthy; 1, minor symptoms or signs, able to run; 2, able to walk >5 m without assistance, but unable to run; 3, able to walk >5 m with assistance; 4, bed- or chair-bound; 5, requiring assisted ventilation for at least part of the day; and 6, dead. “+” indicates the patient had precipitating factors from infectious disease.”-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings